Form 4: Vivani Medical CEO Adam Mendelsohn Acquires Stock Options and RSUs

Adam Mendelsohn, CEO of Vivani Medical, acquired stock options and restricted stock units (RSUs) on May 12, 2025, according to a Form 4 filing.

Summary

• Adam Mendelsohn, the CEO of Vivani Medical, acquired 200,000 common stock options and 100,000 restricted stock units (RSUs) on May 12, 2025.
• The stock options have an exercise price of $1.03 and vest over 4 years.
• The RSUs vest in three stages based on the company's stock price reaching $3.15 for three consecutive days, with subsequent vesting milestones one and two years after the initial target is met.
• If the stock price does not reach the target within four years, the RSUs will expire.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of stock options and RSUs by the CEO suggests confidence in the company's future, but the performance-based vesting of the RSUs also indicates a need to improve the company's stock price.

Positives

• The CEO's acquisition of stock options and RSUs aligns his interests with those of the shareholders.
• The performance-based vesting of the RSUs incentivizes the CEO to drive the company's stock price higher.
• The vesting schedule of the stock options encourages long-term commitment from the CEO.

Risks

• The RSUs will expire if the stock price does not reach $3.15 within four years, potentially leading to the CEO not realizing the full value of the grant.
• The vesting of the stock options and RSUs is contingent on the CEO's continued service, creating a potential risk if he were to leave the company.

Future Outlook

The vesting of the RSUs is contingent on the company's stock price performance, suggesting a focus on increasing shareholder value.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to monitor potential insider trading activity and assess management's confidence in the company's future prospects.

Comparison to Industry Standards

• Stock option and RSU grants are common forms of executive compensation in the pharmaceutical and biotechnology industries.
• Vesting schedules and performance-based vesting conditions are also standard practices to align executive incentives with shareholder value creation.
• Comparable companies such as Amgen, Gilead Sciences, and Biogen also utilize stock options and RSUs as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the CEO's acquisition of stock options and RSUs as a positive sign, aligning his interests with theirs.
• Employees may be motivated by the performance-based vesting of the RSUs, as it incentivizes the CEO to improve the company's performance.

Key Dates

Keywords

Vivani Medical, Adam Mendelsohn, stock options, RSUs, Form 4, insider trading, executive compensation